| |
|
|
|
Aeglea BioTherapeutics Inc.  
|
|
8.16 0.11 (0.01%) |
08-21 16:00 |
|
Open: |
8.1 |
Pre close: |
8.05 |
Target:
|
10.63
|
|
High: |
8.27 |
Low: |
8.04 |
Resistance:
|
9.10
10.63
|
|
Volume: |
43,606 |
Market Cap: |
236M |
Support:
|
7.62
6.70
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
8.00
 |
MACD |
MACD(12,26):
|
0.18 |
|
MA(20): |
8.23 |
Signal(12,26,9): |
0.24  |
|
MA(100): |
7.15 |
Stochastic Oscillator |
%K(14,3):
|
41.26 |
|
MA(250): |
8.00 |
%D(3): |
36.11 |
|
Average Volume(K) |
3-Month: |
16517
|
52-Week |
High:
|
11.16 |
|
10-Days: |
6773 |
Low: |
5.99 |
|
RSI |
RSI(14):
|
58.19 |
Change(%): |
-16.3 |
|
Financials, Statistics and Valuation |
|
EPS |
-2.300 |
Return on Equity (ttm) |
-71.7 |
Shares Out. (M) |
16.81 |
|
EPS Est. Current Year |
-2.070 |
Return on Assets (ttm) |
-40.5 |
Shares Float (M) |
16.95 |
|
EPS Est. Next Year |
-2.190 |
PEG Ratio |
0.00 |
% Held by Insiders |
8.07 |
|
EPS Est. Next Quarter |
-0.580 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
67.20 |
|
Forward EPS |
-2.600 |
Gross Profit (p.s.) |
-1.953 |
Shares Short (K) |
322 |
|
Book Value (p.s.) |
3.450 |
EBITDA (p.s.) |
-3.776 |
P/E |
-3.55 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
2.37 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-47.89 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-26.38 |
P/CF |
-2.86 |
|
|
|
|
|
|
